CCPM, GPhA endorse biogenerics legislation

February 19, 2007

The Coalition for Competitive Pharmaceutical Market (CCPM) is one of the many groups that applauded the bipartisan introduction of the Access to Life Saving-Medicine Act of 2007, which aims to bring safe, effective, and more affordable biogeneric drugs to Americans. CCPM is an organization of large national employers, health plans, pharmacy benefit managers, chain pharmacies, generic drug manufacturers and others committed to improving consumer access to high quality, affordable generic medicines and promoting a vigorous, competitive prescription drug market. CCPM chair Annette Guarisco said, "CCPM endorses this legislation as a safe, science-based approach that appropriately leaves full discretion to the FDA to determine the safety and efficacy of biogenerics." GPhA also applauded the proposed legislation with the following statement, "The Access to Life-Saving Medicine Act will create a safe, clear, and efficient abbreviated FDA approval pathway so patients can have timely access to biogenerics." The legislation was sponsored by Reps. Henry Waxman (D, Calif.), Jo Ann Emerson (R, Mo.), Frank Pallone (D, N.J.), and Rahm Emanuel (D, Ill.) and Sens. Charles Schumer (D, N.Y.), Hillary Clinton (D, N.Y.), Debbie Stabenow (D, Miss.), Patrick Leahy (D, Vt.), Susan Collins (R, Maine), and David Vitter (R, La.).

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.